Patient Counseling Section Of Labeling Should Be Limited, FDA Advises
This article was originally published in The Pink Sheet Daily
Executive Summary
Only the most important, not necessarily the most common, side effects should be included in the section denoting what a health care provider should tell a patient, FDA’s draft guidance says; section was mandated under 2006 physician labeling rule.
You may also be interested in...
New Drug Labeling Format Encourages Physician-Patient Interaction
FDA's final labeling rule creates several new sections designed to facilitate physicians' drug prescribing practices
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.